| Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma D Qualls, JS Abramson Haematologica 104 (1), 25, 2019 | 59 | 2019 |
| Evolution of body composition following autologous and allogeneic hematopoietic cell transplantation: incidence of sarcopenia and association with clinical outcomes Z DeFilipp, FM Troschel, DA Qualls, S Li, MW Kuklinski, ME Kempner, ... Biology of Blood and Marrow Transplantation 24 (8), 1741-1747, 2018 | 47 | 2018 |
| Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis D Qualls, H Seethapathy, H Bates, S Tajmir, P Heidari, P Endres, ... Journal for ImmunoTherapy of Cancer 7, 1-7, 2019 | 33 | 2019 |
| CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience ML Palomba, D Qualls, S Monette, S Sethi, A Dogan, M Roshal, ... Journal for Immunotherapy of Cancer 10 (2), 2022 | 28 | 2022 |
| Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses O Lyudovyk, JY Kim, D Qualls, MA Hwee, YH Lin, SR Boutemine, ... Cancer Cell 40 (7), 738-753. e5, 2022 | 25 | 2022 |
| Prospects in the management of patients with follicular lymphoma beyond first-line therapy D Qualls, G Salles Haematologica 107 (1), 19, 2022 | 23 | 2022 |
| Utility of magnetic resonance imaging in diagnosing cervical spine injury in children with severe traumatic brain injury D Qualls, JR Leonard, M Keller, J Pineda, JC Leonard Journal of Trauma and Acute Care Surgery 78 (6), 1122-1128, 2015 | 22 | 2015 |
| Tafasitamab and lenalidomide in relapsed/refractory large B cell lymphoma (R/R LBCL): real world outcomes in a multicenter retrospective study D Qualls, MJ Buege, P Dao, PF Caimi, SC Rutherford, G Wehmeyer, ... Blood 140 (Supplement 1), 787-789, 2022 | 19 | 2022 |
| Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: a case series and review of the literature DA Qualls, GD Lewis, V Sanchorawala, A Staron American Journal of Transplantation 19 (11), 3185-3190, 2019 | 19 | 2019 |
| High-dose thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation as upfront consolidation for systemic non-Hodgkin lymphoma with synchronous central … D Qualls, A Sullivan, S Li, AM Brunner, K Collier, E Hochberg, P Armand, ... Clinical Lymphoma Myeloma and Leukemia 17 (12), 884-888, 2017 | 17 | 2017 |
| Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study DA Qualls, N Lambert, PF Caimi, M Merrill, P Pullarkat, RC Godby, ... Blood 142 (26), 2327-2331, 2023 | 16 | 2023 |
| Optimizing CAR T cell therapy in lymphoma D Qualls, G Salles Hematological Oncology 39, 104-112, 2021 | 15 | 2021 |
| Features of wild-type human SOD1 limit interactions with misfolded aggregates of mouse G86R Sod1 DA Qualls, M Prudencio, BLT Roberts, K Crosby, H Brown, DR Borchelt Molecular neurodegeneration 8, 1-15, 2013 | 14 | 2013 |
| Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance DJ Shepherd, ES Tabb, K Kunitoki, ML Zhang, M Kem, J Barth, DA Qualls, ... Modern Pathology 35 (5), 615-624, 2022 | 9 | 2022 |
| An analysis of interactions between fluorescently-tagged mutant and wild-type SOD1 in intracellular inclusions DA Qualls, K Crosby, H Brown, DR Borchelt PLoS One 8 (12), e83981, 2013 | 8 | 2013 |
| A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma D Qualls, HY Lam, K Whiting, A Kumar, M Matasar, C Owens, C Nichols, ... Blood Advances 6 (18), 5262-5266, 2022 | 4 | 2022 |
| Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label … D Qualls, A Noy, D Straus, M Matasar, C Moskowitz, V Seshan, A Dogan, ... Leukemia & lymphoma 64 (3), 738-741, 2023 | 3 | 2023 |
| Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era D Qualls, BS Imber, M Okwali, PA Hamlin, A Kumar, OB Lahoud, ... British journal of haematology 200 (4), 524, 2023 | 2 | 2023 |
| Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies D Qualls, A Kumar, ZD Epstein-Peterson Leukemia & lymphoma 63 (11), 2515-2527, 2022 | 2 | 2022 |
| Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers E Ayers, V Zelikson, A Gurumurthi, Y Sawalha, K Annunzio, A Saha, ... Blood 142, 312, 2023 | 1 | 2023 |
